CAR T-cell therapy in acute myeloid leukemia

References

1. 1.↵
   1. Saultz JN,
   2. Garzon R

   . Acute myeloid leukemia: a concise review. J Clin Med 2016; 5: 33.

   OpenUrl
2. 2.↵
   1. Dong Y,
   2. Shi O,
   3. Zeng Q,
   4. Lu X,
   5. Wang W,
   6. Li Y, et al.

   Leukemia incidence trends at the global, regional, and national level between 1990-2017. Exp Hematol Oncol 2020; 9: 14.

   OpenUrl
3. 3.↵
   1. Siegel RL,
   2. Miller KD,
   3. Wagle NS,
   4. Jemal A

   . Cancer statistics, 2023. CA Cancer J Clin 2023; 73: 17-48.

   OpenUrlCrossRefPubMed
4. 4.↵
   American Cancer Society. Key statistics for acute myeloid leukemia. [Updated 2023; accessed 2023 Nov 30]. Available from: https://www.cancer.org/cancer/types/acute-myeloid-leukemia/about/key-statistics.html
5. 5.↵
   1. Juliusson G,
   2. Lehmann S,
   3. Lazarevic V

   . Epidemiology and Etiology of AML. [Updated 2021; 2024 Apr 9]. Available from: https://doi.org/10.1007/978-3-030-72676-8
6. 6.↵
   1. Mundt KA,
   2. Dell LD,
   3. Boffetta P,
   4. Beckett EM,
   5. Lynch HN,
   6. Desai VJ, et al.

   The importance of evaluating specific myeloid malignancies in epidemiological studies of environmental carcinogens. BMC Cancer 2021; 21: 227.

   OpenUrl
7. 7.↵
   1. Short NJ,
   2. Kantarjian H,
   3. Ravandi F,
   4. Daver N

   . Emerging treatment paradigms with FLT3 inhibitors in acute myeloid leukemia. Ther Adv Hematol 2019; 10: 2040620719827310.

   OpenUrlCrossRefPubMed
8. 8.
   1. Dhillon S

   . Ivosidenib: first global approval. Drugs 2018; 78: 1509-1516.

   OpenUrl
9. 9.
   1. Kim ES

   . Enasidenib: first global approval. Drugs 2017; 77: 1705-1711.

   OpenUrl
10. 10.
    1. Deeks ED

    . Venetoclax: first global approval. Drugs 2016; 76: 979-987.

    OpenUrlCrossRefPubMed
11. 11.↵
    1. Gasiorowski RE,
    2. Clark GJ,
    3. Bradstock K,
    4. Hart DN

    . Antibody therapy for acute myeloid leukaemia. Br J Haematol 2014; 164: 481-495.

    OpenUrlCrossRefPubMed
12. 12.↵
    1. Kavanagh S,
    2. Murphy T,
    3. Law A,
    4. Yehudai D,
    5. Ho JM,
    6. Chan S, et al.

    Emerging therapies for acute myeloid leukemia: translating biology into the clinic. JCI Insight 2017; 2: e95679.

    OpenUrl
13. 13.↵
    1. Sadelain M,
    2. Brentjens R,
    3. Rivière I

    . The basic principles of chimeric antigen receptor design. Cancer Discov 2013; 3: 388-398.

    OpenUrlAbstract/FREE Full Text
14. 14.↵
    1. Jackson HJ,
    2. Rafiq S,
    3. Brentjens RJ

    . Driving CAR T-cells forward. Nat Rev Clin Oncol 2016; 13: 370-383.

    OpenUrlCrossRefPubMed
15. 15.↵
    1. Maude SL,
    2. Laetsch TW,
    3. Buechner J,
    4. Rives S,
    5. Boyer M,
    6. Bittencourt H, et al.

    Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med 2018; 378: 439-448.

    OpenUrlCrossRefPubMed
16. 16.↵
    1. Locke FL,
    2. Ghobadi A,
    3. Jacobson CA,
    4. Miklos DB,
    5. Lekakis LJ,
    6. Oluwole OO, et al.

    Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. Lancet Oncol 2019; 20: 31-42.

    OpenUrlCrossRefPubMed
17. 17.
    1. Wang M,
    2. Munoz J,
    3. Goy A,
    4. Locke FL,
    5. Jacobson CA,
    6. Hill BT, et al.

    KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. N Engl J Med 2020; 382: 1331-1342.

    OpenUrlCrossRefPubMed
18. 18.↵
    1. Abramson JS,
    2. Palomba ML,
    3. Gordon LI,
    4. Lunning MA,
    5. Wang M,
    6. Arnason J, et al.

    Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet 2020; 396: 839-852.

    OpenUrlCrossRefPubMed
19. 19.↵
    1. Munshi NC,
    2. Anderson LD Jr.,
    3. Shah N,
    4. Madduri D,
    5. Berdeja J,
    6. Lonial S, et al.

    Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med 2021; 384: 705-716.

    OpenUrlCrossRefPubMed
20. 20.↵
    1. Martin T,
    2. Usmani SZ,
    3. Berdeja JG,
    4. Agha M,
    5. Cohen AD,
    6. Hari P, et al.

    Ciltacabtagene autoleucel, an anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed/refractory multiple myeloma: CARTITUDE-1 2-year follow-up. J Clin Oncol 2023; 41: 1265-1274.

    OpenUrlCrossRef
21. 21.↵
    1. Ritchie DS,
    2. Neeson PJ,
    3. Khot A,
    4. Peinert S,
    5. Tai T,
    6. Tainton K, et al.

    Persistence and efficacy of second generation CAR T-cell against the LeY antigen in acute myeloid leukemia. Mol Ther 2013; 21: 2122-2129.

    OpenUrlCrossRefPubMed
22. 22.↵
    1. Griffin JD,
    2. Linch D,
    3. Sabbath K,
    4. Larcom P,
    5. Schlossman SF

    . A monoclonal antibody reactive with normal and leukemic human myeloid progenitor cells. Leuk Res 1984; 8: 521-534.

    OpenUrlCrossRefPubMed
23. 23.↵
    1. Hauswirth AW,
    2. Florian S,
    3. Printz D,
    4. Sotlar K,
    5. Krauth MT,
    6. Fritsch G, et al.

    Expression of the target receptor CD33 in CD34+/CD38-/CD123+ AML stem cells. Eur J Clin Invest 2007; 37: 73-82.

    OpenUrlCrossRefPubMed
24. 24.↵
    1. O’Hear C,
    2. Heiber JF,
    3. Schubert I,
    4. Fey G,
    5. Geiger TL

    . Anti-CD33 chimeric antigen receptor targeting of acute myeloid leukemia. Haematologica 2015; 100: 336-344.

    OpenUrlAbstract/FREE Full Text
25. 25.↵
    1. Kenderian SS,
    2. Ruella M,
    3. Shestova O,
    4. Klichinsky M,
    5. Aikawa V,
    6. Morrissette JJ, et al.

    CD33-specific chimeric antigen receptor T-cells exhibit potent preclinical activity against human acute myeloid leukemia. Leukemia 2015; 29: 1637-1647.

    OpenUrlCrossRefPubMed
26. 26.↵
    1. Liu Y,
    2. Wang S,
    3. Schubert ML,
    4. Lauk A,
    5. Yao H,
    6. Blank MF, et al.

    CD33-directed immunotherapy with third-generation chimeric antigen receptor T-cells and gemtuzumab ozogamicin in intact and CD33-edited acute myeloid leukemia and hematopoietic stem and progenitor cells. Int J Cancer 2022; 150: 1141-1155.

    OpenUrl
27. 27.↵
    1. Qin H,
    2. Yang L,
    3. Chukinas JA,
    4. Shah N,
    5. Tarun S,
    6. Pouzolles M, et al.

    Systematic preclinical evaluation of CD33-directed chimeric antigen receptor T-cell immunotherapy for acute myeloid leukemia defines optimized construct design. J Immunother Cancer 2021; 9: e003149.

    OpenUrlAbstract/FREE Full Text
28. 28.↵
    1. Wang QS,
    2. Wang Y,
    3. Lv HY,
    4. Han QW,
    5. Fan H,
    6. Guo B, et al.

    Treatment of CD33-directed chimeric antigen receptor-modified T-cells in one patient with relapsed and refractory acute myeloid leukemia. Mol Ther 2015; 23: 184-191.

    OpenUrlCrossRefPubMed
29. 29.↵
    1. Tambaro FP,
    2. Singh H,
    3. Jones E,
    4. Rytting M,
    5. Mahadeo KM,
    6. Thompson P, et al.

    Autologous CD33-CAR-T cells for treatment of relapsed/refractory acute myelogenous leukemia. Leukemia 2021; 35: 3282-3286.

    OpenUrl
30. 30.↵
    1. Haubner S,
    2. Perna F,
    3. Köhnke T,
    4. Schmidt C,
    5. Berman S,
    6. Augsberger C, et al.

    Coexpression profile of leukemic stem cell markers for combinatorial targeted therapy in AML. Leukemia 2019; 33: 64-74.

    OpenUrlCrossRefPubMed
31. 31.↵
    1. Jordan CT,
    2. Upchurch D,
    3. Szilvassy SJ,
    4. Guzman ML,
    5. Howard DS,
    6. Pettigrew AL, et al.

    The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells. Leukemia 2000; 14: 1777-1784.

    OpenUrlCrossRefPubMedWeb of Science
32. 32.↵
    1. Testa U,
    2. Pelosi E,
    3. Castelli G

    . CD123 as a therapeutic target in the treatment of hematological malignancies. Cancers (Basel) 2019; 11: 1358.

    OpenUrl
33. 33.↵
    1. Arcangeli S,
    2. Rotiroti MC,
    3. Bardelli M,
    4. Simonelli L,
    5. Magnani CF,
    6. Biondi A, et al.

    Balance of anti-CD123 chimeric antigen receptor binding affinity and density for the targeting of acute myeloid leukemia. Mol Ther 2017; 25: 1933-1945.

    OpenUrlCrossRef
34. 34.↵
    1. Sugita M,
    2. Galetto R,
    3. Zong H,
    4. Ewing-Crystal N,
    5. Trujillo-Alonso V,
    6. Mencia-Trinchant N, et al.

    Allogeneic TCRαβ deficient CAR T-cells targeting CD123 in acute myeloid leukemia. Nat Commun 2022; 13: 2227.

    OpenUrl
35. 35.↵
    1. Baroni ML,
    2. Sanchez Martinez D,
    3. Gutierrez Aguera F,
    4. Roca Ho H,
    5. Castella M,
    6. Zanetti SR, et al.

    41BB-based and CD28-based CD123-redirected T-cells ablate human normal hematopoiesis in vivo. J Immunother Cancer 2020; 8: e000845.

    OpenUrlAbstract/FREE Full Text
36. 36.↵
    1. Tasian SK

    . Acute myeloid leukemia chimeric antigen receptor T-cell immunotherapy: how far up the road have we traveled? Ther Adv Hematol 2018; 9: 135-148.

    OpenUrlPubMed
37. 37.↵
    1. Cummins KD,
    2. Gill S

    . Chimeric antigen receptor T-cell therapy for acute myeloid leukemia: how close to reality? Haematologica 2019; 104: 1302-1308.

    OpenUrlFREE Full Text
38. 38.↵
    1. Loff S,
    2. Dietrich J,
    3. Meyer JE,
    4. Riewaldt J,
    5. Spehr J,
    6. von Bonin M, et al.

    Rapidly switchable universal CAR-T cells for treatment of CD123-positive leukemia. Mol Ther Oncolytics 2020; 17: 408-420.

    OpenUrl
39. 39.↵
    1. El Khawanky N,
    2. Hughes A,
    3. Yu W,
    4. Myburgh R,
    5. Matschulla T,
    6. Taromi S, et al.

    Demethylating therapy increases anti-CD123 CAR T-cell cytotoxicity against acute myeloid leukemia. Nat Commun 2021; 12: 6436.

    OpenUrl
40. 40.↵
    1. Budde L,
    2. Song JY,
    3. Kim Y,
    4. Blanchard S,
    5. Wagner J,
    6. Stein AS, et al.

    Remissions of acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm following treatment with CD123-specific CAR T-cells: a first-in-human clinical trial. Blood 2017; 130: 811.

    OpenUrl
41. 41.↵
    1. Budde LE,
    2. Song J,
    3. Real M Del,
    4. Kim Y,
    5. Toribio C,
    6. Wood B, et al.

    Abstract PR14: CD123CAR displays clinical activity in relapsed/refractory (r/r) acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm (BPDCN): safety and efficacy results from a phase 1 study. Cancer Immunol Res 2020; 8: PR14-PR14.

    OpenUrlCrossRef
42. 42.↵
    1. Chen Y,
    2. Wang J,
    3. Zhang F,
    4. Liu P

    . A perspective of immunotherapy for acute myeloid leukemia: current advances and challenges. Front Pharmacol 2023; 14: 1151032.

    OpenUrlCrossRef
43. 43.↵
    1. Murad JM,
    2. Baumeister SH,
    3. Werner L,
    4. Daley H,
    5. Trébéden-Negre H,
    6. Reder J, et al.

    Manufacturing development and clinical production of NKG2D chimeric antigen receptor-expressing T-cells for autologous adoptive cell therapy. Cytotherapy 2018; 20: 952-963.

    OpenUrlCrossRef
44. 44.↵
    1. Li KX,
    2. Wu HY,
    3. Pan WY,
    4. Guo MQ,
    5. Qiu DZ,
    6. He YJ, et al.

    A novel approach for relapsed/refractory FLT3mut+ acute myeloid leukaemia: synergistic effect of the combination of bispecific FLT3scFv/NKG2D-CAR T-cells and gilteritinib. Mol Cancer 2022; 21: 66.

    OpenUrl
45. 45.↵
    1. Sallman DA,
    2. Kerre T,
    3. Havelange V,
    4. Poiré X,
    5. Lewalle P,
    6. Wang ES, et al.

    CYAD-01, an autologous NKG2D-based CAR T-cell therapy, in relapsed or refractory acute myeloid leukaemia and myelodysplastic syndromes or multiple myeloma (THINK): haematological cohorts of the dose escalation segment of a phase 1 trial. Lancet Haematol 2023; 10: e191-e202.

    OpenUrl
46. 46.↵
    1. Baumeister SH,
    2. Murad J,
    3. Werner L,
    4. Daley H,
    5. Trebeden-Negre H,
    6. Gicobi JK, et al.

    Phase I trial of autologous CAR T-cells targeting NKG2D ligands in patients with AML/MDS and multiple myeloma. Cancer Immunol Res 2019; 7: 100-112.

    OpenUrlAbstract/FREE Full Text
47. 47.↵
    1. Lonez C,
    2. Verma B,
    3. Hendlisz A,
    4. Aftimos P,
    5. Awada A,
    6. Van Den Neste E, et al.

    Study protocol for THINK: a multinational open-label phase I study to assess the safety and clinical activity of multiple administrations of NKR-2 in patients with different metastatic tumour types. BMJ Open 2017; 7: e017075.

    OpenUrlAbstract/FREE Full Text
48. 48.↵
    1. Ma H,
    2. Padmanabhan IS,
    3. Parmar S,
    4. Gong Y

    . Targeting CLL-1 for acute myeloid leukemia therapy. J Hematol Oncol 2019; 12: 41.

    OpenUrlPubMed
49. 49.↵
    1. Wang J,
    2. Chen S,
    3. Xiao W,
    4. Li W,
    5. Wang L,
    6. Yang S, et al.

    CAR-T cells targeting CLL-1 as an approach to treat acute myeloid leukemia. J Hematol Oncol 2018; 11: 7.

    OpenUrlCrossRefPubMed
50. 50.↵
    1. Zhang H,
    2. Gan WT,
    3. Hao WG,
    4. Wang PF,
    5. Li ZY,
    6. Chang LJ

    . Successful anti-CLL1 CAR T-cell therapy in secondary acute myeloid leukemia. Front Oncol 2020; 10: 685.

    OpenUrl
51. 51.↵
    1. Zhang H,
    2. Wang P,
    3. Li Z,
    4. He Y,
    5. Gan W,
    6. Jiang H

    . Anti-CLL1 chimeric antigen receptor T-cell therapy in children with relapsed/refractory acute myeloid leukemia. Clin Cancer Res 2021; 27: 3549-3555.

    OpenUrlAbstract/FREE Full Text
52. 52.↵
    1. Jin X,
    2. Zhang M,
    3. Sun R,
    4. Lyu H,
    5. Xiao X,
    6. Zhang X, et al.

    First-in-human phase I study of CLL-1 CAR-T cells in adults with relapsed/refractory acute myeloid leukemia. J Hematol Oncol 2022; 15: 88.

    OpenUrlCrossRef
53. 53.↵
    1. Liu F,
    2. Cao Y,
    3. Pinz K,
    4. Ma Y,
    5. Wada M,
    6. Chen K, et al.

    First-in-human CLL1-CD33 compound CAR T-cell therapy induces complete remission in patients with refractory acute myeloid leukemia: update on phase 1 clinical trial. Blood 2018; 132: 901.

    OpenUrlCrossRef
54. 54.↵
    1. Levis M,
    2. Small D

    . FLT3: it does matter in leukemia. Leukemia 2003; 17: 1738-1752.

    OpenUrlCrossRefPubMedWeb of Science
55. 55.↵
    1. Jetani H,
    2. Garcia-Cadenas I,
    3. Nerreter T,
    4. Thomas S,
    5. Rydzek J,
    6. Meijide JB, et al.

    CAR T-cells targeting FLT3 have potent activity against FLT3-ITD+ AML and act synergistically with the FLT3-inhibitor crenolanib. Leukemia 2018; 32: 1168-1179.

    OpenUrlCrossRef
56. 56.↵
    1. Sommer C,
    2. Cheng HY,
    3. Nguyen D,
    4. Dettling D,
    5. Yeung YA,
    6. Sutton J, et al.

    Allogeneic FLT3 CAR T-cells with an off-switch exhibit potent activity against AML and can be depleted to expedite bone marrow recovery. Mol Ther 2020; 28: 2237-2251.

    OpenUrlPubMed
57. 57.↵
    1. Wang Y,
    2. Xu Y,
    3. Li S,
    4. Liu J,
    5. Xing Y,
    6. Xing H, et al.

    Targeting FLT3 in acute myeloid leukemia using ligand-based chimeric antigen receptor-engineered T-cells. J Hematol Oncol 2018; 11: 60.

    OpenUrlCrossRefPubMed
58. 58.↵
    1. Neu S,
    2. Geiselhart A,
    3. Sproll M,
    4. Hahn D,
    5. Kuçi S,
    6. Niethammer D, et al.

    Expression of CD44 isoforms by highly enriched CD34-positive cells in cord blood, bone marrow and leukaphereses. Bone Marrow Transplant 1997; 20: 593-598.

    OpenUrlCrossRefPubMed
59. 59.↵
    1. Bendall LJ,
    2. Bradstock KF,
    3. Gottlieb DJ

    . Expression of CD44 variant exons in acute myeloid leukemia is more common and more complex than that observed in normal blood, bone marrow or CD34+ cells. Leukemia 2000; 14: 1239-1246.

    OpenUrlCrossRefPubMed
60. 60.↵
    1. Casucci M,
    2. Nicolis di Robilant B,
    3. Falcone L,
    4. Camisa B,
    5. Norelli M,
    6. Genovese P, et al.

    CD44v6-targeted T-cells mediate potent antitumor effects against acute myeloid leukemia and multiple myeloma. Blood 2013; 122: 3461-3472.

    OpenUrlAbstract/FREE Full Text
61. 61.↵
    1. Stornaiuolo A,
    2. Valentinis B,
    3. Sirini C,
    4. Scavullo C,
    5. Asperti C,
    6. Zhou D, et al.

    Characterization and functional analysis of CD44v6.CAR T-cells endowed with a new low-affinity nerve growth factor receptor-based spacer. Hum Gene Ther 2021; 32: 744-760.

    OpenUrl
62. 62.↵
    1. Chang H,
    2. Salma F,
    3. Yi QL,
    4. Patterson B,
    5. Brien B,
    6. Minden MD

    . Prognostic relevance of immunophenotyping in 379 patients with acute myeloid leukemia. Leuk Res 2004; 28: 43-48.

    OpenUrlCrossRefPubMed
63. 63.↵
    1. Kim MY,
    2. Cooper ML,
    3. Jacobs MT,
    4. Ritchey JK,
    5. Hollaway J,
    6. Fehniger TA, et al.

    CD7-deleted hematopoietic stem cells can restore immunity after CAR T-cell therapy. JCI Insight 2021; 6: e149819.

    OpenUrl
64. 64.↵
    1. Gomes-Silva D,
    2. Atilla E,
    3. Atilla PA,
    4. Mo F,
    5. Tashiro H,
    6. Srinivasan M, et al.

    CD7 CAR T-cells for the therapy of acute myeloid leukemia. Mol Ther 2019; 27: 272-280.

    OpenUrlCrossRef
65. 65.↵
    1. Zhong X,
    2. Ma H

    . Targeting CD38 for acute leukemia. Front Oncol 2022; 12: 1007783.

    OpenUrlCrossRefPubMed
66. 66.↵
    1. McKenzie JL,
    2. Gan OI,
    3. Doedens M,
    4. Dick JE

    . Reversible cell surface expression of CD38 on CD34-positive human hematopoietic repopulating cells. Exp Hematol 2007; 35: 1429-1436.

    OpenUrlCrossRefPubMed
67. 67.↵
    1. An N,
    2. Pan Y,
    3. Yang L,
    4. Zhang Q,
    5. Deng S,
    6. Zhang Q, et al.

    Anti-acute myeloid leukemia activity of CD38-CAR-T cells with PI3Kd downregulation. Mol Pharm 2023; 20: 2426-2435.

    OpenUrl
68. 68.↵
    1. Majzner RG,
    2. Mackall CL

    . Tumor antigen escape from CAR T-cell therapy. Cancer Discov 2018; 8: 1219-1226.

    OpenUrlAbstract/FREE Full Text
69. 69.↵
    1. Xu X,
    2. Sun Q,
    3. Liang X,
    4. Chen Z,
    5. Zhang X,
    6. Zhou X, et al.

    Mechanisms of relapse after CD19 CAR T-cell therapy for acute lymphoblastic leukemia and its prevention and treatment strategies. Front Immunol 2019; 10: 2664.

    OpenUrlPubMed
70. 70.↵
    1. Cohen AD,
    2. Garfall AL,
    3. Stadtmauer EA,
    4. Melenhorst JJ,
    5. Lacey SF,
    6. Lancaster E, et al.

    B-cell maturation antigen-specific CAR T-cells are clinically active in multiple myeloma. J Clin Invest 2019; 129: 2210-2221.

    OpenUrlCrossRefPubMed
71. 71.↵
    1. Brown CE,
    2. Alizadeh D,
    3. Starr R,
    4. Weng L,
    5. Wagner JR,
    6. Naranjo A, et al.

    Regression of glioblastoma after chimeric antigen receptor T-cell therapy. N Engl J Med 2016; 375: 2561-2569.

    OpenUrlCrossRefPubMed
72. 72.↵
    1. Cordoba S,
    2. Onuoha S,
    3. Thomas S,
    4. Pignataro DS,
    5. Hough R,
    6. Ghorashian S, et al.

    CAR T-cells with dual targeting of CD19 and CD22 in pediatric and young adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia: a phase 1 trial. Nat Med 2021; 27: 1797-1805.

    OpenUrlCrossRefPubMed
73. 73.↵
    1. Larson RC,
    2. Kann MC,
    3. Graham C,
    4. Mount CW,
    5. Castano AP,
    6. Lee WH, et al.

    Anti-TACI single and dual-targeting CAR T-cells overcome BCMA antigen loss in multiple myeloma. Nat Commun 2023; 14: 7509.

    OpenUrl
74. 74.↵
    1. Jin X,
    2. Xie D,
    3. Sun R,
    4. Lu W,
    5. Xiao X,
    6. Yu Y, et al.

    CAR-T cells dual-target CD123 and NKG2DLs to eradicate AML cells and selectively target immunosuppressive cells. Oncoimmunology 2023; 12: 2248826.

    OpenUrl
75. 75.↵
    1. Wang Y,
    2. Lu W,
    3. Rohrbacher L,
    4. Flaswinkel H,
    5. Emhardt AJ,
    6. Magno G, et al.

    CD33-TIM3 dual CAR T-cells: enhancing specificity while maintaining efficacy against AML. Blood 2023; 142: 3449.

    OpenUrl
76. 76.↵
    1. Sterner RC,
    2. Sterner RM

    . CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J 2021; 11: 69.

    OpenUrlCrossRefPubMed
77. 77.↵
    1. Steentoft C,
    2. Migliorini D,
    3. King TR,
    4. Mandel U,
    5. June CH,
    6. Posey AD Jr.

    Glycan-directed CAR-T cells. Glycobiology 2018; 28: 656-669.

    OpenUrl
78. 78.↵
    1. Drent E,
    2. Themeli M,
    3. Poels R,
    4. de Jong-Korlaar R,
    5. Yuan H,
    6. de Bruijn J, et al.

    A rational strategy for reducing on-target off-tumor effects of CD38-chimeric antigen receptors by affinity optimization. Mol Ther 2017; 25: 1946-1958.

    OpenUrlCrossRefPubMed
79. 79.↵
    1. Morris EC,
    2. Neelapu SS,
    3. Giavridis T,
    4. Sadelain M

    . Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy. Nat Rev Immunol 2022; 22: 85-96.

    OpenUrlCrossRefPubMed
80. 80.↵
    1. O’Leary MC,
    2. Lu X,
    3. Huang Y,
    4. Lin X,
    5. Mahmood I,
    6. Przepiorka D, et al.

    FDA approval summary: tisagenlecleucel for treatment of patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia. Clin Cancer Res 2019; 25: 1142-1146.

    OpenUrlAbstract/FREE Full Text
81. 81.↵
    1. Sharma P,
    2. Kasamon YL,
    3. Lin X,
    4. Xu Z,
    5. Theoret MR,
    6. Purohit-Sheth T

    . FDA approval summary: axicabtagene ciloleucel for second-line treatment of large B-cell lymphoma. Clin Cancer Res 2023; 29: 4331-4337.

    OpenUrl
82. 82.↵
    1. Santomasso BD,
    2. Park JH,
    3. Salloum D,
    4. Riviere I,
    5. Flynn J,
    6. Mead E, et al.

    Clinical and biological correlates of neurotoxicity associated with CAR T-cell therapy in patients with B-cell acute lymphoblastic leukemia. Cancer Discov 2018; 8: 958-971.

    OpenUrlAbstract/FREE Full Text
83. 83.↵
    1. Frey NV,
    2. Porter DL

    . Cytokine release syndrome with novel therapeutics for acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program 2016; 2016: 567-572.

    OpenUrlAbstract/FREE Full Text
84. 84.↵
    1. Vanhooren J,
    2. Dobbelaere R,
    3. Derpoorter C,
    4. Deneweth L,
    5. Van Camp L,
    6. Uyttebroeck A, et al.

    CAR-T in the treatment of acute myeloid leukemia: barriers and how to overcome them. Hemasphere 2023; 7: e937.

    OpenUrl
85. 85.↵
    1. Milone MC,
    2. Bhoj VG

    . The pharmacology of T-cell therapies. Mol Ther Methods Clin Dev 2018; 8: 210-221.

    OpenUrl
86. 86.↵
    1. Alabanza L,
    2. Pegues M,
    3. Geldres C,
    4. Shi V,
    5. Wiltzius JJW,
    6. Sievers SA, et al.

    Function of novel anti-CD19 chimeric antigen receptors with human variable regions is affected by hinge and transmembrane domains. Mol Ther 2017; 25: 2452-2465.

    OpenUrlCrossRefPubMed
87. 87.↵
    1. Ying Z,
    2. Huang XF,
    3. Xiang X,
    4. Liu Y,
    5. Kang X,
    6. Song Y, et al.

    A safe and potent anti-CD19 CAR T-cell therapy. Nat Med 2019; 25: 947-953.

    OpenUrlCrossRefPubMed
88. 88.↵
    1. Sommermeyer D,
    2. Hill T,
    3. Shamah SM,
    4. Salter AI,
    5. Chen Y,
    6. Mohler KM, et al.

    Fully human CD19-specific chimeric antigen receptors for T-cell therapy. Leukemia 2017; 31: 2191-2199.

    OpenUrlPubMed
89. 89.↵
    1. Sterner RM,
    2. Sakemura R,
    3. Cox MJ,
    4. Yang N,
    5. Khadka RH,
    6. Forsman CL, et al.

    GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts. Blood 2019; 133: 697-709.

    OpenUrlAbstract/FREE Full Text
90. 90.↵
    1. Minagawa K,
    2. Al-Obaidi M,
    3. Di Stasi A

    . Generation of suicide gene-modified chimeric antigen receptor-redirected T-cells for cancer immunotherapy. Methods Mol Biol 2019; 1895: 57-73.

    OpenUrl
91. 91.↵
    1. Di Stasi A,
    2. Tey SK,
    3. Dotti G,
    4. Fujita Y,
    5. Kennedy-Nasser A,
    6. Martinez C, et al.

    Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med 2011; 365: 1673-1683.

    OpenUrlCrossRefPubMedWeb of Science
92. 92.
    1. Juillerat A,
    2. Tkach D,
    3. Busser BW,
    4. Temburni S,
    5. Valton J,
    6. Duclert A, et al.

    Modulation of chimeric antigen receptor surface expression by a small molecule switch. BMC Biotechnol 2019; 19: 44.

    OpenUrlPubMed
93. 93.↵
    1. Mestermann K,
    2. Giavridis T,
    3. Weber J,
    4. Rydzek J,
    5. Frenz S,
    6. Nerreter T, et al.

    The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on/off switch for CAR T-cells. Sci Transl Med 2019; 11.